• HSD132 Analysis of Factors Affecting Medication Adherence in Patients with Hypertension in South Korea

    Dec 1, 2023, 00:00

  • SA28 Evaluation of Disease Epidemiology, Comorbidities, Treatment Patterns, and Healthcare Resource Utilization of Alopecia Areata in United Arab Emirates: A Retrospective Claims Database Study

    Dec 1, 2023, 00:00

  • MT75 Analysis of Manufacturer and Negotiated Price Differential of Digital Health Applications (DIGA) in Germany

    Dec 1, 2023, 00:00

  • EPH147 The Costs of Unaddressed Hearing Loss in Chilean Children with Bilateral Microtia and External Auditory Canal Atresia and Cost Effectiveness of Different Treatment Interventions

    Dec 1, 2023, 00:00

  • SA31 Systematic Versus Rapid Reviews: The Impact of Different Methodologies on the Reviews’ Conclusions

    Dec 1, 2023, 00:00

  • HTA304 The Impact of Different HTA Frameworks on Time to Patient Access: A Case Study Assessing the First Commercial Launch Indications for Lynparza, Tagrisso, Imfinzi, Calquence and Enhertu

    Dec 1, 2023, 00:00

  • EE688 Case for Clear Communication and Justification of Survival Extrapolation Methodology: A Review of NICE Submissions in Oncology

    Dec 1, 2023, 00:00

  • HSD7 Longitudinal Analysis of Diagnostic Procedures for Sleep Disorders in the German In-Patient Sector

    Dec 1, 2023, 00:00

  • EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age

    Dec 1, 2023, 00:00

  • PCR107 (How) Should Cost-Effectiveness Analysis Accommodate Heterogeneity in Patient Preferences?

    Dec 1, 2023, 00:00

  • PCR72 How to Achieve Comprehensive Care for Breast Cancer? Challenges in Chile from the Voice of Patients

    Dec 1, 2023, 00:00

  • EE584 Is Point-of-Care Testing in Emergency Departments Cost-Effective? A Systematic Literature Review

    Dec 1, 2023, 00:00

  • Economic Evaluation

    Dec 1, 2023, 00:00

  • MSR7 Incorporating External Data to Inform Overall Survival Extrapolation: A Review of NICE Health Technology Appraisals for Oncology Drugs

    Dec 1, 2023, 00:00

  • HTA312 The Association of ESMO-Magnitude of Clinical Benefit Scale Scores and Subsidy Decisions of Targeted Therapies for Solid Tumors in Singapore

    Dec 1, 2023, 00:00

  • HTA79 CADTH Reimbursement Recommendations for Mental Illness Health Products: 10-Year Trends in Relation to Non-Mental Illness Health Products and Recommendations From Other HTA Bodies

    Dec 1, 2023, 00:00

  • EE520 Hospital Costs in Resected Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC): A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)

    Dec 1, 2023, 00:00

  • EPH143 Health Behavior and Quality of Life in Women With Endometriosis

    Dec 1, 2023, 00:00

  • EE444 Cost-Effectiveness Analysis of Replacing PCV13 with PCV15 in the Pediatric National Immunization Program of Greece

    Dec 1, 2023, 00:00

  • HTA40 Making MCDA 'Shiny' With an Adaptive Support Tool for Healthcare Decision-Making: An Application in Broad Molecular Testing With R Shiny

    Dec 1, 2023, 00:00

  • EE151 Trade-Off between Comparators Comprehensiveness and Methodological Robustness in Cost-Utility Studies Reviewed By Has in France

    Dec 1, 2023, 00:00

  • MSR148 Methodological Aspects of Composite Measures: A Comparison of Techniques for Rescaling and Aggregation

    Dec 1, 2023, 00:00

  • HPR12 Assessing COA Label Claims Based on Single-Arm Trials in Rare Diseases: A Review of US FDA Labels

    Dec 1, 2023, 00:00

  • EE43 Utilizing Real-World Evidence to Estimate Treatment Costs Among Norwegian Patients with Myasthenia Gravis Treated with Intravenous Immunoglobulin (IVIG)

    Dec 1, 2023, 00:00

  • EE111 Indirect Cost Burden for Individuals Living with Transfusion-Dependent Beta-Thalassemia in Europe

    Dec 1, 2023, 00:00

  • EPH166 Access Trends to Cardiac Implantable Electronic Devices in the Brazilian Public Healthcare System: A Twelve-Year Real World Data Analysis

    Dec 1, 2023, 00:00

  • EE261 Economic Burden of Hemophilic Arthropathy in Patients with Hemophilia

    Dec 1, 2023, 00:00

  • HPR56 Rare Disease Policies and Orphan Drug Designation Processes in European and Asia-Pacific (APAC) Countries

    Dec 1, 2023, 00:00

  • MSR60 Use of External Control Arms (ECAs) in Marketing Applications Submitted to European Medicines Agency (EMA): A Targeted Review

    Dec 1, 2023, 00:00

  • PCR230 Real-World Clinical Characteristics of Patients with Migraine Who Initiated Fremanezumab in Sweden: An Observational, Nationwide Register-Based Study

    Dec 1, 2023, 00:00

  • PCR259 Patient-Reported Experience Along the Psoriatic Disease Patient Journey in Portugal

    Dec 1, 2023, 00:00

  • EE472 Estimation of the Burden of Chronic Kidney Disease in the Argentine Health System

    Dec 1, 2023, 00:00

  • MSR65 The Impact of Censoring Assumptions in the Generation of Individual Patient Data from Kaplan-Meier Estimates

    Dec 1, 2023, 00:00

  • HPR85 Opinions on Sustainable Healthcare Financing Options for Funding New Medical Technologies in ASEAN-6

    Dec 1, 2023, 00:00

  • RWD125 A Health-Related Cost and Mortality Comparison Between Early and Late-Stage Lung Cancer: A Retrospective Cohort Study from a Brazilian Health Management Organization (HMO)

    Dec 1, 2023, 00:00

  • HPR92 Burnt Out or Something More? Investigating Drivers of and Spatial Variation in NHS Staff Turnover Intention

    Dec 1, 2023, 00:00

  • EPH148 Disease Burden of Sickle Cell Disease in Saudi Arabia

    Dec 1, 2023, 00:00

  • EE639 Explorative Cost-Effectiveness Analysis of a Rapid ID/AST Solution for Patients with Bloodstream Infection

    Dec 1, 2023, 00:00

  • PT17 Modelling Treatment Duration in Psoriasis: Examining Extrapolation Approaches and Implications

    Dec 1, 2023, 00:00

  • Award Winners

    Dec 1, 2023, 00:00

  • EE733 Distributional Cost-Effectiveness Analysis: A Case Study on Its Potential Prospects in HTA

    Dec 1, 2023, 00:00

  • HPR157 Challenges and Potential Solutions in Implementing a Bundle Payment Program for Osteoarthritis

    Dec 1, 2023, 00:00

  • EPH81 Clinical Characteristics and Treatment Patterns of Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • EE477 Exploring the Perceived Value of Fixed-Dose Combinations in Type 2 Diabetes Mellitus in the EU4 and the UK

    Dec 1, 2023, 00:00

  • RWD72 Status of the Art on Global Clinical Trials of Patient-Managed Digital Medical Devices (pDMD): 2023 Original Data Analysis From Multiple Sources

    Dec 1, 2023, 00:00

  • OP27 Observations of Patient Preference in the Creation of Treatment Support Materials

    Dec 1, 2023, 00:00

  • HSD104 Comparative Analysis of Legislations and Market Access of Cannabis Medicines in Poland and Ukraine

    Dec 1, 2023, 00:00

  • Organizational Practices

    Dec 1, 2023, 00:00

  • CO20 Use of Inpatient Systemic Chemotherapy and/or Radiotherapy and Related Predictive Factors for Metastatic Urothelial Cancer (mUC): Findings from a Retrospective Observational Study in a Clinical Practice Setting in Italy

    Dec 1, 2023, 00:00

  • CO178 Understanding Physicians’ Decision-Making Practices Related to Biomarker Testing: Analysis of the Adelphi Real-World Ovarian Cancer II Disease Specific Programme (DSPTM)

    Dec 1, 2023, 00:00

  • RWD172 Strategies for the Rational Use of Biologic Therapies in an Integrated Clinic for Immune-Mediated Skin Diseases

    Dec 1, 2023, 00:00

  • HTA353 Analysis of the Impact of Early Access Decisions on Pricing and Reimbursement Decisions in France

    Dec 1, 2023, 00:00

  • HSD57 Adherence Teleassistance-Based Program Impact in a Real-Life Diabetes Colombian Patient Cohort

    Dec 1, 2023, 00:00

  • HPR103 Potential Impacts of the EMA-HMA Join Statement Supporting Biosimilar Interchangeability in Biosimilar Access in the EU

    Dec 1, 2023, 00:00

  • EPH174 Trends in Hospitalization of Patients with Wilson's Disease in Germany

    Dec 1, 2023, 00:00

  • HTA282 Evolution of Timeframes Within the Overall Time-to-Market Since Marketing Authorisation for New Innovative-Presumed Products in France Since the First Published Economic Opinion

    Dec 1, 2023, 00:00

  • EE415 Effect of Vitamin C Use on Cost of Common Cold in Turkiye

    Dec 1, 2023, 00:00

  • PCR84 The Daily Life and Psychosocial Impacts of Friedreich Ataxia: A Qualitative Study of Patient Lived Experiences

    Dec 1, 2023, 00:00

  • CO17 How to Assess Nationwide Population-Based Clinical Benefit of Treatments Using Public Information? Immunotherapies Case Study

    Dec 1, 2023, 00:00

  • PCR55 Unleashing the Power of Social Media Listening: A Promising Tool for Patient-Focused Research

    Dec 1, 2023, 00:00

  • PCR247 Is the Symptomatology of Infantile Tay-Sachs and Infantile Sandhoff Disease Identical? Data from an International Registry

    Dec 1, 2023, 00:00

  • EE302 Value of End-of-Life Health Gains

    Dec 1, 2023, 00:00

  • HSD125 Non-Dispensed Prescriptions from the Public and Private Health Care Sectors: A Comparative Register Study

    Dec 1, 2023, 00:00

  • PCR68 Estimation of Minimal Clinically Important Difference (MCID) for the Tardive Dyskinesia Impact Scale (TDIS), a Tardive Dyskinesia-Specific Patient-Reported Outcome

    Dec 1, 2023, 00:00

  • HPR163 Underinvestment in Pharmaceutical Care and Unmet Pharmaceutical Needs Among Older European Adults

    Dec 1, 2023, 00:00

  • EE335 Burden of COVID-19 Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany—A Retrospective Claims Data Analysis

    Dec 1, 2023, 00:00

  • MSR16 Health-Related Quality of Life Multi-Instrument Comparison for the Use in Children Aged 2-4 Years Old

    Dec 1, 2023, 00:00

  • HTA250 Mapping the VF-14 Onto the EQ-5D-5L: The Potential to Estimate Quality-Adjusted Life-Years Without Generic Quality-of-Life Data in Ophthalmology

    Dec 1, 2023, 00:00

  • HTA46 Relationship Between the Directness of the Evidence and Identification of Added Therapeutic Value: An Analysis of HTA Procedures

    Dec 1, 2023, 00:00

  • PT27 How Much Does TLV Value Rarity? A Review of Reimbursement Decisions on Orphan Drugs in Sweden from 2017 through 2022

    Dec 1, 2023, 00:00

  • EE618 Sacubitril/Valsartan Vs Enalapril Use in Hospitalized Patients with Heart Failure in Spain

    Dec 1, 2023, 00:00

  • EE513 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Large B-Cell Lymphoma—Exploring the Impact of Country Settings and Performance-Based Managed Entry Agreements

    Dec 1, 2023, 00:00

  • HTA39 A Valuable Perspective on Medical Devices – Assesing the Organizational Impact of Health Technologies in Decision-Making

    Dec 1, 2023, 00:00

  • EE614 Evaluating the Cost-Effectiveness of CYP2C19 Genetic Testing in Patients Who Have Experienced an Ischaemic Stroke or Transient Ischaemic Attack in England and Wales

    Dec 1, 2023, 00:00

  • HSD37 Gender Disparities in Treatment and Costs of Rectal Cancer at the End of Life Phase—An Analysis of German Claims Data

    Dec 1, 2023, 00:00

  • HSD95 Unmet Needs and Value Proposition for Genital Warts Novel Treatments: Payer Perception

    Dec 1, 2023, 00:00

  • HTA313 The Same but Different: Inconsistencies in Key Cost-Effectiveness Assumptions for Curative Therapies across Clinically Similar NICE Appraisals

    Dec 1, 2023, 00:00

  • EE72 A Cost-Effectiveness Analysis of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-Small Cell Lung Cancer in Portugal

    Dec 1, 2023, 00:00

  • EE41 Cost Effectiveness of Romosozumab Followed by Alendronate Versus Teriparatide in the Treatment of Severe Osteoporosis in Greece

    Dec 1, 2023, 00:00

  • EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database

    Dec 1, 2023, 00:00

  • CO175 OCTOPUS: Ambispective Observational Study Describing Diagnosis and Treatment Patterns in Adults with Metastatic NSCLC with BRAF V600E Mutation in Clinical Practice, to Assess Treatment Effectiveness and Quality of Life (TIP)

    Dec 1, 2023, 00:00

  • EE646 Waiting Times and Cost-Effectiveness: An Early Case Study in Cognitive Behavioral Therapy for Anxiety

    Dec 1, 2023, 00:00

  • PCR124 Qualitative Exploration of the Patient Experience of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Via Concept Elicitation Interviews with Patients and Neurologists

    Dec 1, 2023, 00:00

  • EE498 Cost-per-Responder Analysis of Bimekizumab Vs Other Licensed Anti-Interleukin Therapies in Psoriatic Arthritis from a UK Perspective

    Dec 1, 2023, 00:00

  • PCR138 An International Study of Patient and Caregiver-Reported Burden and Quality of Life in Wiskott-Aldrich Syndrome

    Dec 1, 2023, 00:00

  • HPR97 Healthcare Systems Resilience and the COVID-19 Emergency: How Care Can Be Improved Within the Current Budget and Resources Constraint by Increasing the Efficiency of Healthcare Delivery

    Dec 1, 2023, 00:00

  • CO52 Comparative Analysis of Tabelecleucel Versus Standard of Care in Patients with EBV+ PTLD Following Hematopoietic Cell Transplant (HCT) or Solid Organ Transplant (SOT)

    Dec 1, 2023, 00:00

  • OP10 The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

    Dec 1, 2023, 00:00

  • EPH212 The Acceptability of Human Papillomavirus Vaccination in the United Kingdom: A Review of the Literature on Barriers and Facilitators to Vaccination

    Dec 1, 2023, 00:00

  • HTA172 Value of French Framework for Early Access Programs for the HTA Appraisal in the Rare Disease Spa The Example of Lanadelumab in Patients With Hereditary Angioedema

    Dec 1, 2023, 00:00

  • EE329 Budget Impact Analysis of Adding Risankizumab and Upadacitinib for the Treatment of Inflammatory Bowel Disease in the Kingdom of Saudi Arabia

    Dec 1, 2023, 00:00

  • EE281 Predicted UK Health Care Associated Cost-Savings and Health-Related Quality of Life Benefits of Introducing a Digital Leakage Notification System for People Living with a Stoma

    Dec 1, 2023, 00:00

  • HTA4 The Challenges of Health Economic Modeling for Mental Health, Behavioral, and Neurodevelopmental Conditions

    Dec 1, 2023, 00:00

  • EPH30 Impact of Paternal Treatment on Birth Outcomes Among Individuals with Autoimmune Rheumatic Diseases

    Dec 1, 2023, 00:00

  • EE485 Cost-Effectiveness of a 4 Days-a-Week Triple Therapy in Persons Living with HIV: An Ancillary Study of the Anrs 170 Quatuor Noninferiority Trial

    Dec 1, 2023, 00:00

  • EE255 The Budget Impact of Switching From High to Low Carbon Emission Inhalers in England

    Dec 1, 2023, 00:00

  • SA83 {Maicplus}: An R Package to Support Analysis and Reporting of Matching Adjusted Indirect Treatment Comparisons (MAIC) for HTA Dossiers

    Dec 1, 2023, 00:00

  • SA5 Innovative Direct-to-Physician Retrospective Chart Review Approach: Synthesized Learnings from Completed and Ongoing

    Dec 1, 2023, 00:00

  • HSD121 Study of Effective Treatment of Genital Herpes in Women in Ukraine

    Dec 1, 2023, 00:00

  • EPH53 Leave or Stay? Influencing Factors of Intention to Leave or Stay in Healthcare Profession After Coronavirus Pandemic Among Frontline Nurses

    Dec 1, 2023, 00:00

  • MSR147 Accounting for Study Heterogeneity When Modelling the Multi-State Natural History of Rare Diseases

    Dec 1, 2023, 00:00

  • EE726 Economics Costs Associated with Hyperkalemia in Argentina

    Dec 1, 2023, 00:00

  • PT21 Evaluation and Reimbursement of Digital Therapeutics in Germany, France, Belgium and England

    Dec 1, 2023, 00:00

  • PCR270 Development of a Quality Appraisal Tool for Systematic Literature Reviews of Studies Eliciting Health State Utility Values (HSUVs): A Delphi Consensus Approach

    Dec 1, 2023, 00:00

  • EE89 Cost-Effectiveness Analysis of Onasemnogene Abeparvovec-Xioi (Zolgensma®) and Best Supportive Care Treatment for Spinal Muscular Atrophy I in the Netherlands With Early-Treatment Scenario

    Dec 1, 2023, 00:00

  • HTA341 Egyptian Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Applications

    Dec 1, 2023, 00:00

  • PCR4 Impact of Obesity on Health-Related Quality of Life, Sleep, and Work – a Multinational Survey

    Dec 1, 2023, 00:00

  • MSR35 Beyond HbA1c: A Contemporary Approach to Modelling Type 2 Diabetes Within the Updated Cardiff T2D Model

    Dec 1, 2023, 00:00

  • MT14 Inequity in Access to Breast Reconstruction Techniques in Belgian Health System: Is it Justified?

    Dec 1, 2023, 00:00

  • MSR85 Psoriasis Symptoms and Impacts Measure: Identifying Key Items Reflecting Core Symptoms of Patients with Plaque Psoriasis

    Dec 1, 2023, 00:00

  • PCR28 Facilitating and Accelerating Patient-Centered Outcomes Measures Awareness and Use in Clinical Research in Rare Diseases

    Dec 1, 2023, 00:00

  • EE571 Indirect Costs and Out-of-Pocket Expenses of Chronic Kidney Disease on Dialysis in Bogota, Colombia

    Dec 1, 2023, 00:00

  • HPR83 The Price Is Right or Is It? Navigating the Inflation Reduction Act (IRA) With Payer Perspectives on Evidence Needs, Fair Market Pricing, and Patient Access Implications

    Dec 1, 2023, 00:00

  • EE35 Social and Economic Burden of Hepatitis C in Russia

    Dec 1, 2023, 00:00

  • EE735 Cost of Chimeric Antigen Receptor (CAR) T-Cell Therapy Related Toxicities

    Dec 1, 2023, 00:00

  • EPH58 The Risk of First and Recurrent Mace Associated with Elevated Lp(A) in a Primary Prevention Population

    Dec 1, 2023, 00:00

  • HTA11 Drivers of Positive Health Technology Assessment Outcomes for Oncology Drugs in Three Global Markets

    Dec 1, 2023, 00:00

  • HPR138 How Are Patient Experience Data Reported in Regulatory Evaluation of Medicinal Products? A Document Analysis of European Public Assessment Reports

    Dec 1, 2023, 00:00

  • RWD123 The Impact of COVID-19 on Treatment of Patients With Ovarian Cancer in England

    Dec 1, 2023, 00:00

  • RWD145 Devastating Loss of Life Expectancy and Quality-Adjusted Life Years after Stroke in Brazil: A Focus on Hemorrhagic Subtypes

    Dec 1, 2023, 00:00

  • EE388 Cost of Illness for Advanced Hepatocellular Carcinoma (aHCC) in Ontario, Canada

    Dec 1, 2023, 00:00

  • EE24 Budget Impact of Stepping Off Patients from Long-Term Inappropriate Proton Pump Inhibitors (PPIs) Use to Episodic Alginate Treatment

    Dec 1, 2023, 00:00

  • EPH146 Epidemiological Insights in Cutaneous Lupus Erythematosus: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • OP19 Monoclonal Antibodies in Oncology: A Comparative Analysis of Subcutaneous Form Use Between Paris University Hospitals (AP-HP) Versus French Hospitals

    Dec 1, 2023, 00:00

  • EPH158 Impact of Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) Related Cancers Elimination on Treatment Patterns in the United Kingdom (HELP-UK)

    Dec 1, 2023, 00:00

  • EPH67 Epidemiology and Economic Burden of Tick-Borne Encephalitis Hospitalizations in Mainland Fran 2014-2021 Analysis of the PMSI Database

    Dec 1, 2023, 00:00

  • MSR110 Four Alternative Methodologies for Simulated Treatment Comparison: How Could the Use of Simulation be Re-Invigorated

    Dec 1, 2023, 00:00

  • EE744 Invasive Meningococcal Disease Economic Burden: A Comprehensive Analysis

    Dec 1, 2023, 00:00

  • P42 Enhancing the Understanding of Phenotypic Outcomes in Sickle Cell Disease (SCD) Through a Comparison Between Data Collected Through App-Based Home-Reported Outcomes (HROs) Versus Qualitative Methodologies

    Dec 1, 2023, 00:00

  • EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial

    Dec 1, 2023, 00:00

  • HTA182 The EU Regulation on HTA: Developing an Adapted Market Access Framework for Pharmaceutical Assets

    Dec 1, 2023, 00:00

  • EPH100 Public Health Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in Mexico

    Dec 1, 2023, 00:00

  • RWD130 Healthcare Resource Utilization for Pediatric and Adolescent Duchenne Muscular Dystrophy Patients: Analysis of Real-World Data

    Dec 1, 2023, 00:00

  • EE499 Cost-Effectiveness Analysis of Using the Fixed-Dose Combination of Levodopa/Carbidopa/Entacapone in Patients With Parkinson’s Disease in Kazakhstan

    Dec 1, 2023, 00:00

  • EE67 Insurer and Patient Costs for Repeat Breast Surgery After Initial Lumpectomy for Breast Cancer

    Dec 1, 2023, 00:00

  • HPR25 Germany: Leading the Way for Digital Health Technology Assessment in Europe

    Dec 1, 2023, 00:00

  • HPR62 Impact of GKV Financial Stabilization Act on Drug Pricing in Germany – Early Experiences of the Reform

    Dec 1, 2023, 00:00

  • EE105 anti-VEGFs Use in Neovascular Age-Related Macular Degeneration: An Analysis of the National Report on Medicines Use in Italy

    Dec 1, 2023, 00:00

  • PCR241 The Experience of Patients Living with Multiple Myeloma: Unmet Needs Associated with Diagnosis, Treatment, and Living with the Condition

    Dec 1, 2023, 00:00

  • PCR93 Actinic Keratosis: Patient Perceptions and Expectations for Treatment (REAKT Study)

    Dec 1, 2023, 00:00

  • HTA293 Challenges and Opportunities in Implementing the EUnetHTA21 Methodological Guidelines in the Context of EU HTA Regulation: Perspectives From Different Stakeholders on Different Markets (France, Italy, and Poland)

    Dec 1, 2023, 00:00

  • MSR134 The Impact of Loneliness on Health Service Use and Health-Related Quality of Life Among Informal Carers in Australia

    Dec 1, 2023, 00:00

  • RWD115 Assessing and Comparing Inpatient Hospitalization for Mental Disorders in the United States and European OECD Countries

    Dec 1, 2023, 00:00

  • EE734 Cost Consequences of Using Clevidipine in Cardiac Surgery from the Perspective of a US Hospital

    Dec 1, 2023, 00:00

  • EE634 Resource Utilization and Costs Related to Inflammatory Bowel Disease: A Longitudinal Analysis Based on Routine Data from Two German Statutory Health Insurance Providers

    Dec 1, 2023, 00:00

  • RWD91 Hospital Efficiency Impact of Spectral CT Versus Conventional CT in Diagnosis of Patients Suspected of Occult Cancer in the UK

    Dec 1, 2023, 00:00

  • PCR173 Identifying Behaviors Practiced By Individuals to Avoid COVID-19: Development of the Content of the Physical Distancing Scale – COVID-19 (PDS-C19)

    Dec 1, 2023, 00:00

  • EPH170 Epidemiology of Stroke in Bulgaria

    Dec 1, 2023, 00:00

  • EE462 Same Day Discharge after Percutaneous Transluminal Coronary Angioplasty (PTCA): Is It Cost Saving?

    Dec 1, 2023, 00:00

  • PCR71 Using Schedule for the Evaluation of Individual Quality of Life (SEIQoL) and Computer Adapted Testing (CAT) in Current Practices

    Dec 1, 2023, 00:00

  • EPH24 Changes in Prescribing of Systemic Cancer Therapies in England: A Nationwide Analysis of Community and Hospital Medicines Utilisation

    Dec 1, 2023, 00:00

  • EE301 Consumption Value of a Quality-Adjusted Life Year: A Time Trade-Off for Income Analysis of Hungarian Cross-Sectional Data

    Dec 1, 2023, 00:00

  • RWD73 Exposing the True Economic Impact of Stroke: A Comparative Analysis of Time-Driven Activity-Based Costing and Reimbursement Methods in Brazil

    Dec 1, 2023, 00:00

  • MSR19 Disease Diagnosis and Severity Prediction: Artificial Intelligence Applications in Hemophilia A

    Dec 1, 2023, 00:00

  • The Relationship Between Pharmaceutical Innovation and Cancer Mortality in Spain, From 1999 to 2016

    Dec 1, 2023, 00:00

  • EPH120 Explaining the Differences in Social Distancing Behavior in the EU During the COVID-19 Pandemic

    Dec 1, 2023, 00:00

  • PCR12 Construct Validity of a New Migraine Satisfaction with Treatment Questionnaire

    Dec 1, 2023, 00:00

  • HPR4 Transferable Exclusivity Vouchers: A Silver Bullet?

    Dec 1, 2023, 00:00

  • MT72 Effectiveness of Drone Technology on Access to Blood and Its Product in the Eastern Region of Ghana: A Cross-Sectional Study

    Dec 1, 2023, 00:00

  • CO9 Post-Discharge Mortality in Patients with Mental Illness Hospitalized Compulsorily in Accordance with the Provisions of Article 29 of the Japanese Mental Health and Welfare Law

    Dec 1, 2023, 00:00

  • CO92 Clinician-Reported Outcome Measure for Palonosetron Versus Standard of Care in Chemotherapy-Induced Nausea and Vomiting in Egypt

    Dec 1, 2023, 00:00

  • EE71 Cost-Effectiveness Analysis of Using Foundationone Liquid CDx in Patients With Advanced Non-Small Cell Lung Cancer in Whom Tissue-Based Testing Is Not Feasible

    Dec 1, 2023, 00:00

  • EE705 The Healthcare Resource Utilisation and Associated Costs for Patients with Newly Diagnosed Fragile X Syndrome

    Dec 1, 2023, 00:00

  • HTA225 New HTA Model for Digitally Supported Managed Care: Lessons From Parkinson's Disease

    Dec 1, 2023, 00:00

  • RWD30 Applying Transportability Methods to Real-World Data: A Scoping Review

    Dec 1, 2023, 00:00

  • HSD71 Management of Care for Patients With Actinic Keratosis in Fran Reakt Study

    Dec 1, 2023, 00:00

  • MSR120 A Method for Adjusting US Health State Utilities for Use in the UK

    Dec 1, 2023, 00:00

  • EE558 The Cost-Effectiveness of Budesonide/Formoterol Maintenance and Reliever Therapy Versus Salmeterol/Fluticasone Plus As-Needed Salbutamol Among Asthma Patients ≥12 Years in China

    Dec 1, 2023, 00:00

  • HTA318 Delays in NICE Highly Special Technology (HST) Appraisal for Medicines That Treat Ultra-Orphan Conditions

    Dec 1, 2023, 00:00

  • PCR165 Accessibility Vs Standardization: A Study of Electronic Implementation of Patient-Reported Outcomes Measures with Vision-Impaired Participants

    Dec 1, 2023, 00:00

  • EE721 Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Pregnancy, Inflammatory Bowel Disease, Heart Failure and Bariatric Surgery Under the Payer’s Perspective of the Supplementary System in Brazil

    Dec 1, 2023, 00:00

  • CO42 4P Care and Adjusting Therapy for Hypothyroidism – A Potential to Reduce Costs of Healthcare and Loss of Productivity

    Dec 1, 2023, 00:00

  • EPH270 Impacts of Different SARS-CoV-2 Variants on Hospital Usage and Performance in the United Arab Emirates: A Comparison Among Alpha, Delta, and Omicron

    Dec 1, 2023, 00:00

  • EE450 Evaluating Price Trends in Supplements from 2018 to 2022 in Turkiye

    Dec 1, 2023, 00:00

  • MT23 Hypoglossal Nerve Stimulation in Obstructive Sleep Apnea: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HPR120 Investigating the Nature and Scope of Innovative Payment and Pricing Schemes for Health Technologies

    Dec 1, 2023, 00:00

  • EPH57 The Market Dynamics of GP IIb/IIIa Inhibitors in Germany: A Closer Look at Eptifibatide and Aggrastat

    Dec 1, 2023, 00:00

  • RWD31 The Impact of Advanced Training on Operational Efficiency in Robotic-Assisted Rectal Resection

    Dec 1, 2023, 00:00

  • EPH56 The Impact of the COVID-19 Pandemic on Cardiovascular Disease Prevention and Corresponding Geographical Inequalities in England: Interrupted Time Series Analysis

    Dec 1, 2023, 00:00

  • PCR172 Physical Distancing to Avoid COVID-19 and the Association With Humanistic Burden in Immunocompromised Adults – The Eagle Study

    Dec 1, 2023, 00:00

  • EE231 Model-Based Assessment of the Costs and Benefits of Directly Mailing Self-Sampling HPV Kits to Non-Participants in Cervical Screening in the Czech Republic

    Dec 1, 2023, 00:00

  • RWD105 Identifying and Appraising Fit-for-Purpose Data Sources for Real World Evidence Studies: A Structured Approach to Conducting Data Source Feasibility Assessments

    Dec 1, 2023, 00:00

  • MSR33 Improving Analysis of Continuous Predictors: Advantages of Fractional Polynomial Transformations (FP) and Interpretation of “Non-Linear” Odds Ratios (OR) or Hazard Ratios (HR)

    Dec 1, 2023, 00:00

  • MT21 Clinical Application of Circulating Tumor Cells in Melanoma Patients: Overview of Current Available Data

    Dec 1, 2023, 00:00

  • EE77 The Cost-Effectiveness of Tradition Chinese Medicine Icaritin Versus Cinobufotalin in Patients with Unresectable Advanced Hepatocellular Carcinoma in China

    Dec 1, 2023, 00:00

  • PCR249 Quality of Life of Moroccan Children with Rare Diseases: Evidence from Real-World Data

    Dec 1, 2023, 00:00

  • EPH31 Systematic Literature Review on the Global Epidemiology of Angelman Syndrome

    Dec 1, 2023, 00:00

  • EE155 Economic Burden of Obstructive Hypertrophic Cardiomyopathy in France

    Dec 1, 2023, 00:00

  • HTA82 Surrogate Measures and the Health Technology Assessment of Cancer Drugs in Ireland: A Retrospective Analysis of EMA Cancer Drug Indication Approvals Between 2017 and 2022 and Recommendations Made By the NCPE in Ireland

    Dec 1, 2023, 00:00

  • EPH217 Discriminant Validity of EQ-5D-Y-3L Between Children-Reported Health-Related Quality of Life and Parent-Reported Developmental Disabilities

    Dec 1, 2023, 00:00

  • EE422 Health Economic Modelling of Current Population Health Management Interventions for CKD in the UK Using a Population-Level Markov Model

    Dec 1, 2023, 00:00

  • HTA196 HTA Guidance Updates and Usage of Real-World Evidence (RWE) in Reimbursement Decisions—A 2023 Perspective

    Dec 1, 2023, 00:00

  • EE244 Healthcare Resource Utilization and Costs in Patients with Alagille Syndrome Using Population-Based Healthcare Data from South Korea

    Dec 1, 2023, 00:00

  • PCR200 Characteristics at Baseline of Patients with Asthma and Prior Systemic Corticosteroid Use Initiating Dupilumab Enrolled in the Real-World Study Rapid

    Dec 1, 2023, 00:00

  • EE97 Budget Impact Analysis with and without Performance-Based Managed Entry Agreement (PBMEA) of Different Treatments for Spinal Muscular Atrophy (SMA) in the Kingdom of Saudi Arabia

    Dec 1, 2023, 00:00

  • RWD20 Health Care Resource Utilization Patterns in Finnish Multiple Myeloma Patients: A Population-Based Cohort Study

    Dec 1, 2023, 00:00

  • RWD103 NVX-CoV2373 Patient Characteristics in Germany: Real-World Retrospective Database Study Shows Most Vaccine Recipients Were Among the High Risk Category

    Dec 1, 2023, 00:00

  • HPR194 New Framework for Early Access to Drugs in Fran Feedback After a One-Year Use in University Public Hospitals of Paris

    Dec 1, 2023, 00:00

  • HTA308 Market Access for Anti-Cancer Drugs: Is the Demonstration of a Clinical Benefit on Survival Correlated With Price Level?

    Dec 1, 2023, 00:00

  • HPR149 Generic Pricing Policy Frees Up $1 Billion: Statin Pricing and Expenditure from 2010-2022 in Australia.

    Dec 1, 2023, 00:00

  • CO159 A Bayesian Network Meta-Analysis (NMA) for Evaluating the Relative Efficacy of Dual Therapy Combinations of Dapagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

    Dec 1, 2023, 00:00

  • EE28 Cost-Effectiveness Formulation of PCR-Test Screening for COVID-19 Regarding Multiple Factors in Epidemic

    Dec 1, 2023, 00:00

  • EE10 Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy Versus Drug Therapy in Patients for 1.5 Primary Prevention in China: An Analysis Using the Improve SCA Study

    Dec 1, 2023, 00:00

  • MSR24 Shaping the Value Equation in Digital Healthcare: A Holistic Perspective on Patient, System, and Provider Interactions

    Dec 1, 2023, 00:00

  • HPR195 Market Access Implications of Early Access to Medicines Scheme in the UK

    Dec 1, 2023, 00:00

  • RWD157 Assessment of Real-World Treatment Patterns and Healthcare Resource Utilization (HCRU) in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma (RRMM) from the US Optum Database

    Dec 1, 2023, 00:00

  • EE31 Economic Burden of Hospitalized Respiratory Syncytial Virus Infection Among Children in Spain, 2016–2019

    Dec 1, 2023, 00:00

  • MSR127 How to Estimate 95% Confidence Intervals When Combining Bootstrapping and Multiple Imputation in Economic Evaluations: A Simulation Study

    Dec 1, 2023, 00:00

  • HTA203 Identification and Comparison of HTA Tools Suitable for Low- and Middle-Income Countries

    Dec 1, 2023, 00:00

  • RWD38 Implement a Direct-to-Patient Application to Recruit Diverse Patients and Collect Real-World Data

    Dec 1, 2023, 00:00

  • PCR85 Facilitating the Identification of Appropriate Patient-Centered Outcome Measures (PCOMS) in Rare Disease (RD) Clinical Research Using Functional Impacts Matching

    Dec 1, 2023, 00:00

  • MT30 Coverage and Payment Implications for Breakthrough Medical Devices Following Translational Coverage of Emerging Technologies (TCET) Proposed Rule in the US

    Dec 1, 2023, 00:00

  • HTA274 Similarities and Differences in Health Technology Assessment (HTA) Bodies Considerations for Decision-Making: Use of Patient Preference Studies

    Dec 1, 2023, 00:00

  • CO98 Health Outcomes and Cost-Effectiveness of Atezolizumab in Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • SA14 "I've Got a Text!” Feedback from Prospective Participants on the Use of SMS Surveys in Real-World Studies

    Dec 1, 2023, 00:00

  • PCR161 Population Norms for the SF-36 Health Status Measure in Hungary

    Dec 1, 2023, 00:00

  • P16 What Trade-Offs Are Women Willing to Make When Choosing Between Potential Treatments for Moderate-to-Severe Vasomotor Symptoms Due to Menopause?

    Dec 1, 2023, 00:00

  • EPH165 Assessing Public Health Models in Fran A Systematic Review

    Dec 1, 2023, 00:00

  • EE518 An Updated Cost-Effectiveness Analysis of Axicabtagene Ciloleucel in Second-Line Large B-Cell Lymphoma Patients in the United States

    Dec 1, 2023, 00:00

  • MSR28 Examining Guidance and Key Principles for Conducting Living Systematic Reviews: A Methods Review

    Dec 1, 2023, 00:00

  • HSD66 Treatment Pathway and Unmet Needs of Waldenström Macroglobulinemia: An Exploratory Study from Portugal

    Dec 1, 2023, 00:00

  • RWD35 Health Status Changes of Refugees from North Korea After Defection: Using National-Wide Big Data in South Korea

    Dec 1, 2023, 00:00

  • EE80 Cost-Effectiveness of Ribociclib Plus a Non-Steroidal Aromatase Inhibitor for the Treatment of Pre- and Peri-Menopausal Women with HR+/HER2 Advanced Breast Cancer in Turkey

    Dec 1, 2023, 00:00

  • HTA16 Summary of Economic Evaluations on Onco-Hematology in France By the Has: What Did We Learn?

    Dec 1, 2023, 00:00

  • HPR42 A Review of Approved Managed Entry Agreements in Sweden

    Dec 1, 2023, 00:00

  • EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK

    Dec 1, 2023, 00:00

  • EE628 Cost of Basal Insulin Therapy in Fran An Observational Longitudinal Study

    Dec 1, 2023, 00:00

  • CO170 Treatment Exposure-Adjusted Event Rates (EAERs) for Grade 3/4 AEs Associated with Emerging and Existing Systemic Therapies for mCRC with at Least 2 Prior Lines of Therapy: Informing Payer and Pathway Formulary Decision Making

    Dec 1, 2023, 00:00

  • HTA168 Widening the Value Lens for Child Health Technologies: Development of a Child-Tailored HTA Value Assessment Framework Using Multi-Criteria Decision Analysis Incorporating Patient, Public, and Expert Perspectives

    Dec 1, 2023, 00:00

  • HSD101 Development of an Adjusted Outpatient Surgery Index (AOSI) Using Machine Learning Methods

    Dec 1, 2023, 00:00

  • HPR53 Timely Reimbursement: The Impact of Early Access Programmes in Non-Squamous Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • EE176 Hospitalization Trends for All Intestinal Infectious Diseases Since Introduction of Rotavirus Gastroenteritis (RVGE) Vaccine in Ireland

    Dec 1, 2023, 00:00

  • EE383 Cost-Effectiveness Analysis of Nivolumab Plus Relatlimab (NIVO+RELA) Versus Nivolumab Monotherapy (NIVO) for Patients With Advanced Melanoma in the Netherlands

    Dec 1, 2023, 00:00

  • HPR59 Evolving Global Regulatory Landscape for Approval of Biosimilars: A Structured Literature Review on Current Challenges and Future Considerations

    Dec 1, 2023, 00:00

  • MSR32 Tips for Excel(lent) Modelling or R There Better Alternatives?

    Dec 1, 2023, 00:00

  • PCR169 Prevalence and Predictive Factors of Psychological Distress Among People with Diabetes in France

    Dec 1, 2023, 00:00

  • Projecting the Economic Impact of Compensating Living Kidney Donors in the United States: Cost-Benefit Analysis Demonstrates Substantial Patient and Societal Gains

    Dec 1, 2023, 00:00

  • HTA179 Environmental Impact and Health Technology Assessment: State of Art and Future Perspectives

    Dec 1, 2023, 00:00

  • MSR78 Use of External Control Data to Adjust for Treatment Switching in Cost-Effectiveness Analyses: Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) in Second-Line Relapsed or Refractory Large B-Cell Lymphoma

    Dec 1, 2023, 00:00

  • EE98 Economic Burden of Patients with Paroxysmal Nocturnal Hemoglobinuria in China

    Dec 1, 2023, 00:00

  • OP11 What Are the Critical Success Factors for a Biotech’s First Commercialization in Europe to Ensure the Right Decisions Are Made for Their Company, Customers, and Future Patients?

    Dec 1, 2023, 00:00

  • EPH193 The Role of Adjuvant Atezolizumab in Reducing Recurrence-Related Treatment Costs in Resected Early-Stage PD-L1 High Non-Small Cell Lung Cancer across Europe

    Dec 1, 2023, 00:00

  • EE216 Provision and Public Expenditure of Radiotherapy Services in Greece (2013-2020)

    Dec 1, 2023, 00:00

  • HPR176 Exploring Diverse Health Financing Models in Europe

    Dec 1, 2023, 00:00

  • EE750 Budget Impact Analysis (BIA) of Increased COVID-19 Booster Vaccinations in Austria

    Dec 1, 2023, 00:00

  • HTA249 The Use of Preprints in Health Technology Assessment during Sars-Cov-2 Pandemic

    Dec 1, 2023, 00:00

  • HTA285 The Impact of the Disease Severity Modifier on NICE Technology Appraisal Decisions

    Dec 1, 2023, 00:00

  • EE352 A Budget Impact Analysis of Cladribine in England and Wales for Patients With Highly Active Relapsing-Remitting Multiple Sclerosis (HA-RRMS)

    Dec 1, 2023, 00:00

  • HTA236 A Systematic Review of Clinical Efficacy and Safety Data in Penta-Refractory Multiple Myeloma: Findings Indicate the Challenges for HTA Submission

    Dec 1, 2023, 00:00

  • PCR29 Progressive Disease Milestones and Survival in Duchenne Muscular Dystrophy (DMD): A Model-Based Synthesis for Extrapolating Lifetime Treatment Effects From Clinical Trial Results

    Dec 1, 2023, 00:00

  • HPR136 Designing an Effective Bundle Payment Program for Osteoarthritis

    Dec 1, 2023, 00:00

  • CO162 More Serbia: Molnupiravir Real World Utilization Among COVID-19 Patients in Serbia

    Dec 1, 2023, 00:00

  • EPH41 Cardiovascular and Renal Replacement Risks in Patients with Sub-Optimally Treated Anemia of Non-Dialysis-Dependent Chronic Kidney Disease

    Dec 1, 2023, 00:00

  • MSR79 Matching Plus Regression Adjustment for the Estimation of the Average Treatment Effect on Survival Outcomes: A Case Study with Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma

    Dec 1, 2023, 00:00

  • MSR39 The Performance of Anchored and Unanchored Population Adjustment Methods (MATCHING-ADJUSTED INDIRECT COMPARISON, SIMULATED TREATMENT COMPARISON, AND MULTIPLE IMPUTATION MARGINALIZATION) in Castration Resistant Prostate Cancer

    Dec 1, 2023, 00:00

  • EE22 Hybrid Closed Loops – A Cost-Effective Future for Type 1 Diabetes Standard of Care? An Update to the TA10845 Economic SLR

    Dec 1, 2023, 00:00

  • P56 Trends in Prescription Drug Use Among Adults With Diabetes in the United States From 1999-2018

    Dec 1, 2023, 00:00

  • EE606 Tools for the Critical Appraisal of Health Economic Analyses: A Scoping Review

    Dec 1, 2023, 00:00

  • RWD58 Impact of Bleeds on the Quality of Life of Patients with Haemophilia: Results from a Multinational Real-World Survey

    Dec 1, 2023, 00:00

  • MSR156 Evaluating Bias Associated With Inadequate Variable Selection When Using Inverse Probability of Censoring Weights to Adjust for Treatment Switches in Clinical Trials

    Dec 1, 2023, 00:00

  • EE672 Cost-Effectiveness Analysis of Pembrolizumab for the Adjuvant Treatment of Patients With Renal Cell Carcinoma Who Have Undergone Nephrectomy in Greece

    Dec 1, 2023, 00:00

  • CO155 Trial-Level Endpoint Surrogacy Analysis: Feasibility Assessment and Comparison of Different Methodological Approaches

    Dec 1, 2023, 00:00

  • EE620 Increase in HCM-Related Economic Burden Due to Atrial Fibrillation in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Analysis of 9490 Patients

    Dec 1, 2023, 00:00

  • HPR158 Challenges, Opportunities and Policy Ways Forward to Systematically Embed the Use of Patient Experience Data in Healthcare Decision-Making: Insights From Multi-Stakeholder Interviews

    Dec 1, 2023, 00:00

  • EPH60 Predictive Value of Gensini Score in Severe Coronary Lesions in Algerian Patients Undergoing Coronary Angiography

    Dec 1, 2023, 00:00

  • HTA94 Challenges Facing the Health Technology Assessment (HTA) Submissions of Second Line Treatments for Advanced Oncology

    Dec 1, 2023, 00:00

  • RWD90 How to Reduce the Burden of Travel for the Patients? a Proof of Concept (POC) for Oncological Oral Drugs Distribution Points Analysis

    Dec 1, 2023, 00:00

  • HSD13 The Impact of Co-Locating GP-Led Minor Injury Clinic on Pediatric Emergency Department

    Dec 1, 2023, 00:00

  • PCR223 Characterizing Spillover Effects and Carer Burden in X-Linked Hypophosphatemia

    Dec 1, 2023, 00:00

  • PCR187 Patient-Reported Outcomes in Phase III Randomized Controlled Trials Evaluating First-Line Treatments in Advance/Metastatic Renal Cell Carcinoma: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE543 Cost and Opportunity in Hemophilia: The Economic Impact of Drug Treatment

    Dec 1, 2023, 00:00

  • PCR135 Selecting Preference-Based Measures (PBMS) for Pediatric Studies: A Proposed Decision Making Framework

    Dec 1, 2023, 00:00

  • EE551 Study of Costs of Hereditary Angioedema in Routine Clinical Practi Economic Impact of the Disease Burden in Spain

    Dec 1, 2023, 00:00

  • EE743 Cost Utility Analysis of Influenza Vaccine Among People Aged 50 Years and Older Living with Comorbidities in Egypt

    Dec 1, 2023, 00:00

  • RWD133 Cross Sectional Claims Data Analysis on Myopia Epidemiology and Treatment Options in Germany

    Dec 1, 2023, 00:00

  • CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)

    Dec 1, 2023, 00:00

  • EE224 Out-of-Pocket Health Expenditures of Leukemia and Lymphoma Patients in Portugal

    Dec 1, 2023, 00:00

  • MSR45 Evaluation of the Future Impact of Immuno-Oncology Introduction on Cancer Mortality in Italy

    Dec 1, 2023, 00:00

  • PCR198 Should We be Mapping from Sleep-Specific to Generic Preference-Based Quality-of-Life Instruments? Unravelling the Debate with a Multi-Instrument Mapping Study of 6 Sleep-Specific and 4 Preference-Based Instruments

    Dec 1, 2023, 00:00

  • EE39 Loss of Productivity, Use of Healthcare Resources and Cost Associated with Insomnia

    Dec 1, 2023, 00:00

  • EE748 Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine in Hong Kong

    Dec 1, 2023, 00:00

  • HPR47 Pricing Lottery or Reasonable Algorithm? Insights From the DiGA Arbitration Board

    Dec 1, 2023, 00:00

  • EE19 Cost Utility Analysis of the Flash Glucose Monitoring System in the Management of People With Type 2 Diabetes Mellitus on Basal Insulin Therapy—An Italian Healthcare System Perspective

    Dec 1, 2023, 00:00

  • SA53 The Accuracy of Network Meta-Analysis Feasibility Predictions Based on Data Included Only in the Abstracts of Trial Publications

    Dec 1, 2023, 00:00

  • EE509 Cost-Effectiveness of Multicancer Early Detection (MCED) With Preferential Detection of Clinically Aggressive Cancers

    Dec 1, 2023, 00:00

  • EPH9 Non-Alcoholic Fatty Liver Disease Awareness in the United States: National Health and Nutrition Examination Survey Data 1999-2020

    Dec 1, 2023, 00:00

  • HSD131 Long-Term Impact of a Comprehensive Care Coordination Program on Medicaid Expenditures Among Children and Young Adults with Chronic Diseases

    Dec 1, 2023, 00:00

  • EE704 Risdiplam for the Treatment of Spinal Muscular Atrophy: Impact on the National Healthcare Service During the First 15 Months of Commercialization in Italy

    Dec 1, 2023, 00:00

  • Copyright/Subscription

    Dec 1, 2023, 00:00

  • EE380 Budget-Impact Analysis of Encorafenib with Binimetinib for Unresectable or Metastatic Melanoma in BRAFV600-Mutated Patients in an Argentinian Social Security Payer Setting

    Dec 1, 2023, 00:00

  • RWD14 Endometrial Cancer First Line Treatment in Argentina: ECHOS-A Real-World Study

    Dec 1, 2023, 00:00

  • HTA100 Health Technology Assessment Paradigm in Rare Diseases: Critical Determinants and Recommendations

    Dec 1, 2023, 00:00

  • RWD52 A Machine Learning Model to Facilitate Patient-Level Risk Screening in Myelodysplastic Syndromes (MDS) Patients in Routine Clinical Practice

    Dec 1, 2023, 00:00

  • PCR11 Humanistic and Economic Burden of Multiple System Atrophy: A Systematic Review

    Dec 1, 2023, 00:00

  • HPR180 Evaluating the Success of the National Bundle Payment Program for Osteoarthritis

    Dec 1, 2023, 00:00

  • PT35 Matching-Adjusted Indirect Comparison (MAIC) of Dabrafenib Plus Trametinib Versus Pembrolizumab Plus Chemotherapy in Patients with Treatment-Naive Metastatic BRAF V600 Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • PCR252 Early Steps Towards a Huntington's Disease Burden-of-Illness Model: Estimating Out-of-Pocket Costs for Patients Showing Clinical Symptoms

    Dec 1, 2023, 00:00

  • HTA13 Broadening the Scope: Analysis of Oncology Reimbursement Decisions Following the Cancer Drugs List Introduction in Singapore

    Dec 1, 2023, 00:00

  • EE179 Economic Burden and Health-Related Quality of Life Among Older People With Dementia Living at Home and Their Informal Caregivers in the Milan Metropolitan Area

    Dec 1, 2023, 00:00

  • EPH118 Elevated Amputation Rates in Painful Diabetic Polyneuropathy: Insights from a Real-World Large Payer Data Set

    Dec 1, 2023, 00:00

  • PCR146 Tuberculosis Patients’ Preferences for Improving Tuberculosis Care in Chitwan District, Nepal: A Discrete Choice Experiment

    Dec 1, 2023, 00:00

  • HTA320 Predicting Value and Price of Orphan Drugs: A Comparison Across Europe and the US

    Dec 1, 2023, 00:00

  • MSR27 Inter-Reviewer Reliability of Literature Screening and Data Extraction for Human and Machine-Assisted Systematic Reviews

    Dec 1, 2023, 00:00

  • HTA261 Preparing for the EU Regulation on HTA and Joint Clinical Assessments of Vaccines

    Dec 1, 2023, 00:00

  • EPH162 A Retrospective Analysis of the Public Health Product Tax in Hungary, 2011-2022

    Dec 1, 2023, 00:00

  • MT27 Does Da Vinci Multiport Experience Help a Surgeon Learn the New Da Vinci Single Port System When Performing a Radical Prostatectomy?

    Dec 1, 2023, 00:00

  • HSD3 Treatment and Associated Outcomes of Type-2 Diabetes Mellitus Patients With a Cardiovascular Comorbidity and Comparison With Guideline Recommendations: A German Claims Data Analysis

    Dec 1, 2023, 00:00

  • MSR26 The Use of Copilot, a Generative Artificial Intelligence Tool, as VBA Programming Assistant in Excel-Based Health Economic Models

    Dec 1, 2023, 00:00

  • CO135 A Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of Pharmaceutical Interventions for First-Line (1L) Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer (MCRPC)

    Dec 1, 2023, 00:00

  • EE739 Assessing the Value of Next Generation Sequencing in NSCLC

    Dec 1, 2023, 00:00

  • EPH75 Adverse Event Types and Discontinuation Rate of Alzheimer's Medication Approved by United States Food and Drug Administration (USFDA)

    Dec 1, 2023, 00:00

  • HTA137 Determining Relevant Thresholds for Reimbursement of Healthcare Interventions: Should We Prohibit the Use of the QALY at Last?

    Dec 1, 2023, 00:00

  • HTA69 Health-Related Quality of Life in the German Early Benefit Assessment—An Update

    Dec 1, 2023, 00:00

  • EPH206 Public Health Impact of Nirsevimab Against Lower Respiratory Infections Associated with Respiratory Syncytial Virus Among Chinese Infants

    Dec 1, 2023, 00:00

  • P3 Open-Source Model Framework for Health-Economic Evaluation of Early Treatment in Alzheimer's Disease

    Dec 1, 2023, 00:00

  • EE299 The Absence of Risk Preferences in Health Economics – What Can We Learn From Transport Economics?

    Dec 1, 2023, 00:00

  • HTA213 Undertaking Studies to Inform Public Policy: Managing Data Collection to Ensure Data Quality in the EQ-5D-5L UK Valuation Through the Use of Independent Quality Control Assessments

    Dec 1, 2023, 00:00

  • MSR43 Flexible Parametric and Semi-Parametric Non-Markov Multi-State Models: Estimation, Prediction Simulation

    Dec 1, 2023, 00:00

  • PCR66 Psychometric Validation of PROMIS-Fatigue-MS-8a Questionnaire in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab

    Dec 1, 2023, 00:00

  • PCR168 Diabetes Mellitus Type 1 in Chile: Unveiling the Patient Journey Throughout Coverage Schemes in Young People and Adults

    Dec 1, 2023, 00:00

  • PCR95 Healthcare Resource Utilization for Adults Diagnosed with Moderate to Severe Atopic Dermatitis in Greece (APOLO STUDY)

    Dec 1, 2023, 00:00

  • EE459 Lifetime Healthcare and Long-Term Care Use of Heart Failure Patients in the Netherlands

    Dec 1, 2023, 00:00

  • HPR221 A Reconstruction and Validation of the Rationale Underlying the Ec Proposal to Make Regulatory Data Protection (RDP) Conditional upon Supply in EU Member States

    Dec 1, 2023, 00:00

  • HTA244 Evaluation of the Acceptance of Real-World Evidence (RWE) in Eunethta Joint Clinical Assessments (JCA) to Support Evidence for Reimbursement Decisions

    Dec 1, 2023, 00:00

  • RWD2 Catheter Ablation to Treat Cardiac Arrhythmia in Germany – Trends Based on German Hospital Data

    Dec 1, 2023, 00:00

  • PCR139 'We Have Conversations That Other Couples Don′t Have to Have:' A Qualitative Study of the Impact of Caregiving in Friedreich Ataxia (FA)

    Dec 1, 2023, 00:00

  • MSR68 How to Choose the Right Insulin in Patients with Type 2 Diabetes: A Joint Modeling Method

    Dec 1, 2023, 00:00

  • HTA68 Trends in Northern Ireland HTA Guidance Adoption: NICE Shows Dominance over SMC and AWMSG

    Dec 1, 2023, 00:00

  • EE682 Number Needed to Treat (NNT) Comparing Axicabtagene Ciloleucel and Best Supportive Care for Third Line Diffuse Large B-Cell Lymphoma in Brazil

    Dec 1, 2023, 00:00

  • Psychometric Comparison of EQ-5D-Y, CHU-9D, and PedsQL 4.0 in Chinese Children and Adolescents With Functional Dyspepsia: A Multicenter Study

    Dec 1, 2023, 00:00

  • PCR21 Patient Preferences and Expectations Regarding Leukemia and Lymphoma Treatment: Improving Patient Engagement in Portugal through Quantitative and Qualitative Findings

    Dec 1, 2023, 00:00

  • MSR49 Non-Systematic Literature Reviews: Can AI Enhance Current Methods?

    Dec 1, 2023, 00:00

  • HPR208 Health Related Quality of Life Inequalities in Greece

    Dec 1, 2023, 00:00

  • CO121 Prevalence of Musculoskeletal and Renal Outcomes in Patients With Chronic Hepatitis B Undergoing Antiviral Treatments in a Real-World Setting

    Dec 1, 2023, 00:00

  • EE561 The Comparative Pharmacoeconomic Analysis of Using Different Anti-VEGF Drugs for Diabetic Macular Edema Therapy in Russia

    Dec 1, 2023, 00:00

  • HTA360 A Comparative Assessment of Systematic Literature Review Requirements for Health Technology Assessment, Globally

    Dec 1, 2023, 00:00

  • RWD76 Assessing the External Validity of Thin Database in Spain: A Reliable Source of Real-World Data for Observational Retrospective Research

    Dec 1, 2023, 00:00

  • EPH55 The Prevalence and Comorbidities of Prurigo Nodularis – A Danish Register-Based Study From 1995 to 2021

    Dec 1, 2023, 00:00

  • EE16 Budget Impact Analysis of the Introduction of Dexcom ONE for the Treatment of Patients With T2 Diabetes on an Intensive Insulin Schedule From the Perspective of the Italian Healthcare Payer

    Dec 1, 2023, 00:00

  • RWD88 Investigating the Transferability, at the National Level, of Results from Hemsys, a French Multidisciplinary Concertation Meetings Database in Onco-Hematology, to Generate Real-World Evidence

    Dec 1, 2023, 00:00

  • EE601 Assessing the Barriers to Healthcare Resource Use (HRU) Data Collection and Offering Solutions to Support the Evidence Generation Process in LMICs

    Dec 1, 2023, 00:00

  • EE384 Indirect Cost of HPV-Attributable Cancer in the United Kingdom

    Dec 1, 2023, 00:00

  • PT34 Impact in Health Outcomes of PD-(L)1 Inhibitors to Treat Early Stages Cancers in Switzerland

    Dec 1, 2023, 00:00

  • HSD70 Economic Benefit of Empowering Community Pharmacists in the Diagnosis and Treatment of Acute Sore Throat in England

    Dec 1, 2023, 00:00

  • EE595 Cost-Effectiveness of HPV Catch-up Vaccination Program in Women Aged 13-24 Years in Low-and Middle- Income Country

    Dec 1, 2023, 00:00

  • CO107 Resource Use Associated with Alpelisib for the Treatment of Patients with PROS: A Modeling Approach

    Dec 1, 2023, 00:00

  • HPR175 Estimating the Impact of the Elective Recovery Plan on Reducing Elective Waiting Lists in England

    Dec 1, 2023, 00:00

  • PT8 Five-Year Healthcare Resource Consumption and Direct Costs of Women with a New Diagnosis of Hr+/HER2- Breast Cancer Primary or Advanced: Analysis of a Large Italian Administrative Database

    Dec 1, 2023, 00:00

  • PCR13 The Burden of Informal Caregivers of People Diagnosed With Myasthenia Gravis

    Dec 1, 2023, 00:00

  • EE545 Evaluating the Clinical Burden of Disease and Costs of ANCA-Associated Vasculitis in Spain: Main Findings from the EUVAS Based Registry.

    Dec 1, 2023, 00:00

  • EE198 A Targeted Literature Review of Treatment Sequencing Approaches in Economic Analyses in Relapsing Multiple Sclerosis

    Dec 1, 2023, 00:00

  • EPH262 The Preparedness and Contribution of Community Pharmacists During Public Health Crises

    Dec 1, 2023, 00:00

  • SA32 Exploring the Feasibility of Indication-Based Pricing in the Korea Healthcare System: A Survey Study

    Dec 1, 2023, 00:00

  • HSD30 Real-World Prescribing of GLP-1s Among Patients With Overweight or Obesity in the United States

    Dec 1, 2023, 00:00

  • RWD149 Real-Life Dose Escalation of Patients with Ulcerative Colitis and Crohn’s Disease Undergoing Biologic Treatment in Portugal

    Dec 1, 2023, 00:00

  • HTA286 Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment

    Dec 1, 2023, 00:00

  • CO78 Time to Diagnosis in Hypertrophic Cardiomyopathies and the Association With Adverse Outcomes Post-Diagnosis

    Dec 1, 2023, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2023, 00:00

  • EE217 Cancer-Related Mortality in Turkiye: Years of Life Lost and Productivity Costs

    Dec 1, 2023, 00:00

  • EE33 Targeted Literature Review on the Economic and Quality of Life Burden Caused by Acne

    Dec 1, 2023, 00:00

  • CO111 Clinical Efficacy and Safety of Interventions for Adult Patients With Moderately Severe to Severe Hemophilia B: A Systematic Review

    Dec 1, 2023, 00:00

  • HTA302 A Retrospective Analysis of the Impact of Treatment Effect on HTA Outcomes for Oncology Treatments Assessed in France and Germany

    Dec 1, 2023, 00:00

  • HPR110 From Paper to Patients: Revealing the Impact of the United Kingdoms' (UK) Health Technology Assessment (HTA) Policies on Advanced Therapy Medicinal Products (ATMPS)

    Dec 1, 2023, 00:00

  • EPH124 Validity of Outpatient ICD-10 Codes to Identify Respiratory Syncytial Virus (RSV) – Estimating Sensitivity and Specificity of Health Administrative Claims Data

    Dec 1, 2023, 00:00

  • P22 Disrupting Health Economics: Automating Network Meta-Analyses With AI and Large Language Models

    Dec 1, 2023, 00:00

  • EE143 Cost-Effectiveness of Replacing the Sequence PCV13→PPV23 with PCV20 in the French Adult Pneumococcal Vaccination Program

    Dec 1, 2023, 00:00

  • EE131 Genetic-Guided Pharmacotherapy for Cardiovascular Disease: A Systematic and Critical Review of Economic Evaluations

    Dec 1, 2023, 00:00

  • EE47 Cost of Illness Study of Migraine in Bulgarian Patients

    Dec 1, 2023, 00:00

  • MSR104 Deriving Caregiver Health Utilities from Patient Endpoints: A Predictive Modelling Approach Using Real-World Survey Data

    Dec 1, 2023, 00:00

  • RWD29 Development of a Comprehensive List of Immunosuppressive Therapies to Enable a Multi-Data Source Global Real-World Effectiveness (RWE) Program of Immunocompromised Patients

    Dec 1, 2023, 00:00

  • PCR31 Psychometric Performance of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Questionnaire Among Patients With Paroxysmal Nocturnal Hemoglobinuria

    Dec 1, 2023, 00:00

  • MSR89 Criteria and Methods Applied to Decision-Making to Embark on Late-Stage Clinical Trials With a Multi-Stakeholder Perspective

    Dec 1, 2023, 00:00

  • HPR17 Exploring Heterogeneity in Biosimilars Dynamics in Italy: Results From Three Chronic Therapeutic Areas

    Dec 1, 2023, 00:00

  • HTA85 Will the New Dutch Criteria for Therapeutic Value for Oncology Drugs Create Inequalities in Access between Countries? a Review of Health Technology Assessment Oncology Submissions.

    Dec 1, 2023, 00:00

  • EPH37 Burden of Disease and Cost of Illness of Age Related Macular Degeneration and Diabetic Macular Edema in Portugal

    Dec 1, 2023, 00:00

  • EE303 Cost-Utility Analysis of Roflumilast Cream for Plaque Psoriasis, Including Intertriginous, From the Canadian Societal Perspective

    Dec 1, 2023, 00:00

  • EPH92 The Development of an Interactive Visual Tool to Communicate the Burden of Atopic Dermatitis in Finland

    Dec 1, 2023, 00:00

  • PCR260 Influence of Disease Activity and Angioedema on EQ-5D-5L Utility Scores in Chronic Spontaneous Urticaria

    Dec 1, 2023, 00:00

  • EPH273 Using Real-World Data Sources in England to Quantify the Burden of Non-Alcoholic Steatohepatitis

    Dec 1, 2023, 00:00

  • EPH226 Estimating the Future Prevalence, Costs, and Clinical Impact of Overweight and Obesity Classes I, II, and III in the UK

    Dec 1, 2023, 00:00

  • CO123 Long COVID Symptom Diary: Development of a PRO Instrument to Support Drug Development and Regulatory Submissions in Europe

    Dec 1, 2023, 00:00

  • EE81 Cost-Effectiveness of CDK 4/6I for the Treatment of Postmenopausal Patients With Advanced Breast Cancer HR-Positive, HER2-Negative From the Point of View of the Payer of the Public Health System in Panama

    Dec 1, 2023, 00:00

  • EE150 Usage of Social Return on Investment Modelling in the Analysis of Healthcare Interventions: A Review of Current Utilization

    Dec 1, 2023, 00:00

  • EE9 Cost-Effectiveness of Icosapent Ethyl for Patients at High Cardiovascular Risk with Elevated Triglycerides in Greece

    Dec 1, 2023, 00:00

  • EE94 Current State of Health Economic Models in Hereditary Angioedema

    Dec 1, 2023, 00:00

  • EE660 Real-World Economic Burden and Healthcare Resource Utilization (HCRU) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the United States

    Dec 1, 2023, 00:00

  • CO25 A Systematic Literature Review (SLR) of the Clinical Efficacy and Safety Evidence Associated with Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

    Dec 1, 2023, 00:00

  • MSR154 Qualitative Content Analysis for Concept Elicitation (CACE) in Clinical Outcome Assessment Development

    Dec 1, 2023, 00:00

  • EE110 Economic Analysis of Sugammadex for Neuromuscular Block Reversal for Laparoscopic Surgery from a Single Hospital System in China

    Dec 1, 2023, 00:00

  • HSD60 Real-World Usage of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with Psoriatic Arthritis in Germany

    Dec 1, 2023, 00:00

  • EPH244 Late-Stage Cancer Diagnosis and Systemic Therapy in England Since 2018

    Dec 1, 2023, 00:00

  • EE7 Optimizing Aortic Stenosis Management: Evaluating the Clinical and Economic Impact of Transcatheter and Surgical Valve Replacement in Taiwan

    Dec 1, 2023, 00:00

  • HTA237 Treatment Effect Waning in Immuno-Oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence

    Dec 1, 2023, 00:00

  • EE720 Budget Impact of Preoperative Anemia Management, the First Pillar of Patient Blood Management, on the Romanian Healthcare System

    Dec 1, 2023, 00:00

  • HSD108 Evaluating Electronic Therapeutic Protocols (ETPS) for Diabetes and Heart Failure in Gree Results from a Quantitative Survey Amongst Practicing Physicians

    Dec 1, 2023, 00:00

  • EE181 COVID-19 Related Work Absenteeism and Its Associated Lost Productivity Cost in Germany: A Population-Based Study

    Dec 1, 2023, 00:00

  • HTA289 Optimizing Healthcare Outcomes: Identifying the Conditions for Successful Value-Based Contracts

    Dec 1, 2023, 00:00

  • PCR92 The Experience and Utilization of Patient Reported Outcomes (PROs) in Leber’s Hereditary Optic Neuropathy (LHON): A Targeted Literature Review

    Dec 1, 2023, 00:00

  • MSR105 Construction of External-Control Arms (ECA) in Relapsed and Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • CO88 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis

    Dec 1, 2023, 00:00
  • «
  • 21
  • 22
  • 23 (current)
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • »